367 related articles for article (PubMed ID: 33741670)
21. Oncology nurse competency in chimeric antigen receptor T-cell therapy: A qualitative study.
He J; Li J; Feng LN; Feng LX; Qiang W; Wang W; Dong L
Nurse Educ Today; 2024 Jan; 132():106040. PubMed ID: 37956569
[TBL] [Abstract][Full Text] [Related]
22. Understanding the Canadian adult CT head rule trial: use of the theoretical domains framework for process evaluation.
Curran JA; Brehaut J; Patey AM; Osmond M; Stiell I; Grimshaw JM
Implement Sci; 2013 Feb; 8():25. PubMed ID: 23433082
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
24. Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare professional stakeholders.
Ruiz AS; Fontaine G; Patey AM; Grimshaw JM; Presseau J; Cox J; Dussault C; Kronfli N
Int J Drug Policy; 2022 Nov; 109():103837. PubMed ID: 36030569
[TBL] [Abstract][Full Text] [Related]
25. A qualitative study exploring perceived barriers and enablers to fidelity of training and delivery for an intervention to reduce non-indicated imaging for low back pain.
To D; De Carvalho D; Pike A; Lawrence R; Etchegary H; Patey AM; Toomey E; Hall A
Chiropr Man Therap; 2023 Jan; 31(1):6. PubMed ID: 36721165
[TBL] [Abstract][Full Text] [Related]
26. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
27. Using the Theoretical Domains Framework to Identify Barriers and Enablers to Implementing a Virtual Tertiary-Regional Telemedicine Rounding and Consultation for Kids (TRaC-K) Model: Qualitative Study.
Bele S; Cassidy C; Curran J; Johnson DW; Bailey JAM
J Med Internet Res; 2021 Dec; 23(12):e28610. PubMed ID: 34941561
[TBL] [Abstract][Full Text] [Related]
28. Using the theoretical domains framework to identify barriers and enablers to pediatric asthma management in primary care settings.
Yamada J; Potestio ML; Cave AJ; Sharpe H; Johnson DW; Patey AM; Presseau J; Grimshaw JM
J Asthma; 2018 Nov; 55(11):1223-1236. PubMed ID: 29261346
[TBL] [Abstract][Full Text] [Related]
29. Barriers and enablers for deprescribing benzodiazepine receptor agonists in older adults: a systematic review of qualitative and quantitative studies using the theoretical domains framework.
Evrard P; Pétein C; Beuscart JB; Spinewine A
Implement Sci; 2022 Jul; 17(1):41. PubMed ID: 35804428
[TBL] [Abstract][Full Text] [Related]
30. Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials.
Foster M; Fergusson DA; Hawrysh T; Presseau J; Kekre N; Schwartz S; Castillo G; Asad S; Fox G; Atkins H; Thavorn K; Montroy J; Holt RA; Monfaredi Z; Lalu MM
Res Involv Engagem; 2020; 6():61. PubMed ID: 33072399
[TBL] [Abstract][Full Text] [Related]
31. Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.
Dhawale T; Johnson PC; Boateng K; Barata A; Traeger L; Nelson AM; Lavoie MW; Holmbeck K; Choe J; Nabily A; Tripathi A; Amonoo HL; Frigault M; El-Jawahri A
Transplant Cell Ther; 2024 Apr; 30(4):402.e1-402.e12. PubMed ID: 38262530
[TBL] [Abstract][Full Text] [Related]
32. Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study.
Mao Y; Huang L; Ruan H; Guo Y; Ni S; Ling Y
Support Care Cancer; 2023 Apr; 31(5):303. PubMed ID: 37099077
[TBL] [Abstract][Full Text] [Related]
33. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F
JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451
[TBL] [Abstract][Full Text] [Related]
34. A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams.
Stenson CL; Vidrine J; Dewhurst F; Osborne W; Menne T; Stocker R
Palliat Med; 2023 Feb; 37(2):215-220. PubMed ID: 36428287
[TBL] [Abstract][Full Text] [Related]
35. Supporting Trial Participation in People with the Huntington's Gene: A Patient-Centered, Theory-Guided Survey of Barriers and Enablers.
Carroll K; Hudek N; Bénard A; Presseau J; Richards DP; Susan M; Fergusson DA; Graham ID; Mestre TA; Brehaut JC
J Huntingtons Dis; 2022; 11(4):421-434. PubMed ID: 36155526
[TBL] [Abstract][Full Text] [Related]
36. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
Granit V; Benatar M; Kurtoglu M; Miljković MD; Chahin N; Sahagian G; Feinberg MH; Slansky A; Vu T; Jewell CM; Singer MS; Kalayoglu MV; Howard JF; Mozaffar T;
Lancet Neurol; 2023 Jul; 22(7):578-590. PubMed ID: 37353278
[TBL] [Abstract][Full Text] [Related]
37. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.
Palomba ML; Qualls D; Monette S; Sethi S; Dogan A; Roshal M; Senechal B; Wang X; Rivière I; Sadelain M; Brentjens RJ; Park JH; Smith EL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35173030
[TBL] [Abstract][Full Text] [Related]
38. Barriers and enablers to the implementation of multidisciplinary team meetings: a qualitative study using the theoretical domains framework.
Maharaj AD; Evans SM; Zalcberg JR; Ioannou LJ; Graco M; Croagh D; Pilgrim CHC; Dodson T; Goldstein D; Philip J; Kench JG; Merrett ND; Neale RE; White K; Evans P; Leong T; Green SE
BMJ Qual Saf; 2021 Oct; 30(10):792-803. PubMed ID: 33247002
[TBL] [Abstract][Full Text] [Related]
39. Primary care provider perceptions of enablers and barriers to following guideline-recommended laboratory tests to confirm chronic kidney disease: a qualitative descriptive study.
Nash DM; Garg AX; Brimble KS; Markle-Reid M
BMC Fam Pract; 2018 Dec; 19(1):192. PubMed ID: 30526501
[TBL] [Abstract][Full Text] [Related]
40. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
